Loading company…
Vividion Therapeutics is a San Diego biotech making small molecule cancer and immune drugs, acquired by Bayer in 2021.
Based in California, US, and founded in 2013 by Benjamin Cravatt, Jin-Quan Yu and Phil Baran, Vividion Therapeutics develops small molecule medicines for cancer and immune disorders, using chemoproteomic screening, an integrated data portal and a chemistry library. It received USD 135 million in Series C funding in February 2021 from Boxer Capital, Logos Capital Partners, SB Investment Advisers and Woodline Partners. Bayer AG acquired the company in August 2021 for USD 1.5 billion.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in